Methotrexate Shows Promise for Preventing PVR

Christina J. Flaxel, MD

Show Description +

Christina J. Flaxel, MD, describes the latest data from the phase 3 GUARD trial of methotrexate for the prevention of postoperative proliferative vitreoretinopathy.

Posted: 8/08/2023

Keywords:

retina-meeting-recap

•

Clinical Trials

•

methotrexate

•

Proliferative Vitreoretinopathy (PVR)

Up Next

Name: Methotrexate Shows Promise for Preventing PVR
Uploaded: 2023-08-08T15:29:46+00:00
Description: Christina J. Flaxel, MD, describes the latest data from the phase 3 GUARD trial of methotrexate for the prevention of postoperative proliferative vitreoretinopathy.

Codes for Concurrent GA and Wet AMD

Jong G. Park, MD

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Defining Anti-VEGF Response in CI-DME

Sharon D. Solomon, MD

Faricimab in Underrepresented Patients With DME

Joseph M. Coney, MD, FASRS

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Biosimilars in the Real World

Carl C. Awh, MD, FASRS

An Update on Suprachoroidal RGX-314

David S. Boyer, MD

Treating GA With ANX007

Jeffrey S. Heier, MD

Introducing a TWO-ROP Algorithm

Nimesh A. Patel, MD

When Infectious Retinitis Leads to an RD

Sruthi Arepalli, MD

ILM Flap Versus ILM Peeling for FTMH

Ankoor R. Shah, MD, FASRS

Wet AMD Incidence with GA Therapy

Roger Goldberg, MD, MBA

Tracking Vitreous Opacities After PPV

Shawn C. Kavoussi, MD

Back to All Videos